IGF2BP2 and glioblastoma: IMP2/p62 expression has been reported to correlate with poor prognosis in other cancer entities such as HCC, glioblastoma (GBM), head and neck cancer, breast, and esophageal cancer [7, 8, 10, 14, 25].